e-Therapeutics plc (AIM:ETX), the drug discovery and development company, today announces its full year results for the 12 months ended 31 January 2014.
Operational highlights
Positive interim results from lead cancer drug ETS2101
•Phase I trial in brain cancer, five dose escalation steps completed, no serious drug-related adverse events
Help employers find you! Check out all the jobs and post your resume.
